Abstract:EGFR T790 M accounts for 50% to 60% of cases of non-small-cell lung carcinoma (NSCLC) resistance to the first-generation EGFR tyrosine kinase inhibitors (TKIs). Hence, identifying novel compounds with activity against TKIs resistant is of great value. In this study, twenty honokiol and magnolol derivatives were isolated from the EtOH extract of Magnolia officinalis and the antiproliferative activity was evaluated on HCC827 (19del EGFR mutation), H1975 (L858 R/T790 M EGFR mutation), and H460 (KRAS mutation) cell lines. Among the isolated compounds, piperitylmagnolol (a 3-substituted magnolol derivative) showed the best antiproliferative activity against those three cell lines with the IC50 values of 15.85, 15.60 and 18.60 μM, respectively, which provided a direction for the structural modification of magnolol. Further structural modification led to the synthesis of thirty-one magnolol derivatives, and compounds A13, C1, and C2 exhibited significant and broad-spectrum antiproliferative activity with the IC50 values ranging from 4.81 to 13.54 μM, which were approximately 4- and 8-fold more potent than those of honokiol and magnolol, respectively. Moreover, their aqueous solubility was remarkably improved with 12-, 400- and 105 fold greater than those of honokiol and magnolol. Anti-tumor mechanism research revealed that these three compounds were able to induce cell cycle arrest at G0/G1 phase, cause efficient apoptosis in H1975 cells, and also prevent the migration of HUVECs in a dose-dependent manner through Cdk2, Cdk4, Cyclin E, and Cyclin D1 inhibition as well as up-regulation of cleaved-PARP and cleaved-caspase 3 levels. In in vivo antitumor activity, C2 (10, 30 and 100 mg/kg, po) dose-dependently inhibited the tumor growth in H1975 xenograft model with the tumor inhibition rate of 46.3%, 59.3% and 61.2% respectively, suggesting that C2 is a potential oral anticancer agent deserving further investigation.

Magnolol Inhibits Growth of Gallbladder Cancer Cells Through the P53 Pathway

Magnolol Suppresses Pancreatic Cancer Development in Vivo and in Vitro Via Negatively Regulating TGF-β/Smad Signaling

The Growth of SGC-7901 Tumor Xenografts Was Suppressed by Chinese Bayberry Anthocyanin Extract Through Upregulating KLF6 Gene Expression.

Magnolol Suppresses the Proliferation and Invasion of Cholangiocarcinoma Cells Via Inhibiting the NF-κB Signaling Pathway.

2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression

Unveiling Nature's Potential Weapon: Magnolol's Role in Combating Bladder Cancer by upregulating the miR-124 and inactivating PKC-δ/ERK Axis

Magnolol's Therapeutic Efficacy and Immunomodulatory Effects in Oral Squamous Cell Carcinoma

Galangin, A Flavonoid From Lesser Galangal, Induced Apoptosis Via P53-Dependent Pathway In Ovarian Cancer Cells

Betulinic acid induces apoptosis of gallbladder cancer cells via repressing SCD1.

Magnolol Exerts Anticancer Activity in Hepatocellular Carcinoma Cells Through Regulating Endoplasmic Reticulum Stress-Mediated Apoptotic Signaling

Magnolol Induces Apoptosis and Suppresses Immune Evasion in Non-small Cell Lung Cancer Xenograft Models

Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer

Discovery and Synthesis of Novel Magnolol Derivatives with Potent Anticancer Activity in Non-Small Cell Lung Cancer.

Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells

Magnolol inhibits cancer stemness and IL-6/Stat3 signaling in oral carcinomas

Semisynthesis of novel magnolol-based Mannich base derivatives that suppress cancer cells via inducing autophagy

Magnolin Inhibits Prostate Cancer Cell Growth in Vitro and in Vivo

Apoptosis Induction and ERK/NF‐κB Inactivation Are Associated with Magnolol‐inhibited Tumor Progression in Hepatocellular Carcinoma in Vivo

Oleanolic acid induces mitochondrial-dependent apoptosis and G0/G1 phase arrest in gallbladder cancer cells

The Natural Compound Magnolol Inhibits Invasion and Exhibits Potential in Human Breast Cancer Therapy

Synthesis and evaluation of new compounds bearing 3-(4-aminopiperidin-1-yl)methyl magnolol scaffold as anticancer agents for the treatment of non-small cell lung cancer via targeting autophagy